Significant incidence of braf p.V600E mutations in esophageal cancer sets the stage for potential use of tyrosine kinase inhibitors

Rajasooriyar, C.; Moorthy, T.; Ranatunge, N.; Ginige, A.; Surenthirakumaran, R.

dc.contributor.author	Rajasooriyar, C.
dc.contributor.author	Moorthy, T.
dc.contributor.author	Ranatunge, N.
dc.contributor.author	Ginige, A.
dc.contributor.author	Surenthirakumaran, R.
dc.date.accessioned	2022-09-26T05:46:35Z
dc.date.available	2022-09-26T05:46:35Z
dc.date.issued	2020
dc.identifier.citation	Proceedings JMA-September - 2020	en_US
dc.identifier.uri	http://repo.lib.jfn.ac.lk/ujrr/handle/123456789/7607
dc.language.iso	en	en_US
dc.publisher	Jaffna Medical Association	en_US
dc.subject	Esophageal cancer	en_US
dc.subject	Tyrosine kinase inhibitors	en_US
dc.subject	Mutation	en_US
dc.title	Significant incidence of braf p.V600E mutations in esophageal cancer sets the stage for potential use of tyrosine kinase inhibitors	en_US
dc.type	Research abstract	en_US